Featured Article
Multiple System Atrophy: A Common Form of Atypical Parkinsonism
Multiple system atrophy is a rare, progressive neurodegenerative condition for which there is currently no cure.
Latest
FDA Grants Orphan Drug Designation to Huntington Disease Treatment
In animal studies, the treatment was associated with improvement in both motor and cognitive function.
Inverse Association Between Physical Activity and PD Risk Found in Men
Researchers observed an inverse relationship between moderate to vigorous physical exercise and risk for Parkinson disease.
Chronic Hepatitis C Infection and Parkinsonism: What's the Link?
For patients with chronic hepatitis C, there is a significantly greater risk for developing parkinsonism, however, treatment with PegIFN/RBV may reduce this risk.
Reduced Survival for Patients With Idiopathic Parkinsonism
Patients with idiopathic parkinsonism have reduced survival, although survival is dependent on the type and characteristics of the parkinsonian disorder.
Removing Appendix May Lower Risk for Parkinson Disease
The normal human appendix seems to contain pathogenic forms of α-synuclein, which may impact the risk for developing Parkinson disease.
Type 2 Diabetes May Have Adverse Effect on Parkinson Disease Symptoms, Outcomes
Patients with both Parkinson disease and type 2 diabetes were more likely to have cardiovascular comorbidities than those with only Parkinson disease.
REM Sleep Behavior Disorder Associated With Worse Cognitive Performance in PD-Susceptible Patients
Participants in the RBD group had significantly worse performances on the Symbol Digit Modality Test compared with participants in the hyposmia and NMC cohorts.
Gout Linked to Higher Risk for Incident Parkinson Disease in Older Adults
Gout may be associated with a higher risk for incident PD in older adults.
Gocovri Treatment Effect Maintained for up to 2 Years in PD Patients With Dyskinesia
The open-label safety study included patients from 3 Gocovri dyskinesia efficacy trials (N=223) and evaluated the long-term safety and tolerability of the treatment.
Do β2‐Adrenoreceptor Medications Affect Parkinson Disease Risk?
In order to determine the risk of PD associated with various β2‐adrenoreceptor drugs, the study authors assessed United States Medicare beneficiary data from 2009.
Neurology Advisor Articles
- Surgical, Nonsurgical Treatments for Chronic Migraine: Evidence and Relevancy
- Neurofilament Light Biomarkers Identify Alzheimer Disease Risk in Down Syndrome
- Myoclonic-Atonic Seizures and Lennox-Gastaut Syndrome Present With Overlapping Features, Difficulty in Diagnosis
- Tap Water in Neti Pot Linked to Brain Infection, Death From Balamuthia mandrillaris
- Rituximab Effects in Neuromyelitis Optica Spectrum Disorders
- APOE Genotype Coupled With Chronic Low-Grade Inflammation Increases Alzheimer's Risk
- Unplanned Pregnancy in Women With Epilepsy Increases Risk for Spontaneous Fetal Loss
- Epilepsy, Sleep Apnea, and SUDEP: A Closer Look
- HIT-Related Stress Linked to Burnout Among Physicians
- Risk Up for Later-Born Siblings of Children With ASD, ADHD